Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma

Stock Information for Monopar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Monopar Therapeutics Inc.

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.